TOP TEN perturbations for 1552280_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552280_at
Selected probe(set): 1552280_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552280_at (1552280_at) across 6540 perturbations tested by GENEVESTIGATOR:

HCV-related HCC study 1 / adjacent HCV-related liver tissue (LC)

Relative Expression (log2-ratio):-4.086095
Number of Samples:5 / 4
Experimental HCV-related HCC study 1
Hepatitis C infection related human hepatocellular carcinoma sample.
Control adjacent HCV-related liver tissue (LC)
Histologically normal adjacent liver tissue of a patient with Hepatitis C infection related hepatocellular carcinoma. Patient with liver cirrhosis.

HBV-related HCC study 1 / adjacent HBV-related liver tissue (CH)

Relative Expression (log2-ratio):-3.488165
Number of Samples:5 / 4
Experimental HBV-related HCC study 1
Hepatitis B infection related human hepatocellular carcinoma sample.
Control adjacent HBV-related liver tissue (CH)
Histologically normal adjacent liver tissue of a patient with Hepatitis B infection related hepatocellular carcinoma. Patient with chronic hepatitis.

oxyphilic adenoma study 1 / normal kidney tissue

Relative Expression (log2-ratio):3.484727
Number of Samples:4 / 2
Experimental oxyphilic adenoma study 1
Tumor tissue samples from the kidney of patients with oxyphilic adenoma (renal oncocytoma).
Control normal kidney tissue
Normal fetal kidney tissue samples.

oxyphilic adenoma study 1 / normal kidney tissue

Relative Expression (log2-ratio):3.2626429
Number of Samples:4 / 3
Experimental oxyphilic adenoma study 1
Tumor tissue samples from the kidney of patients with oxyphilic adenoma (renal oncocytoma).
Control normal kidney tissue
Normal adult kidney tissue samples.

HCC study 24 (metastatic) / adjacent liver tissue

Relative Expression (log2-ratio):-2.9288168
Number of Samples:7 / 2
Experimental HCC study 24 (metastatic)
Metastatic tumor liver tissue samples derived from patients with intrahepatic metastatic hepatocellular carcinoma (HCC). Samples were obtained from patients who underwent primary HCC curative hepatic resection at TaipeiVeterans General Hospital in Taiwan.
Control adjacent liver tissue
Normal adjacent liver tissue samples derived from patients with hepatocellular carcinoma (HCC). Samples were obtained from patients who underwent primary HCC curative hepatic resection at TaipeiVeterans General Hospital in Taiwan.

HCC study 24 (primary) / adjacent liver tissue

Relative Expression (log2-ratio):-2.8523226
Number of Samples:3 / 2
Experimental HCC study 24 (primary)
Primary tumor liver tissue samples derived from patients with hepatocellular carcinoma (HCC). Samples were obtained from patients who underwent primary HCC curative hepatic resection at Taipei Veterans General Hospital in Taiwan.
Control adjacent liver tissue
Normal adjacent liver tissue samples derived from patients with hepatocellular carcinoma (HCC). Samples were obtained from patients who underwent primary HCC curative hepatic resection at TaipeiVeterans General Hospital in Taiwan.

renal cell carcinoma study 6 (chromophobe type) / normal kidney tissue

Relative Expression (log2-ratio):2.8445978
Number of Samples:4 / 2
Experimental renal cell carcinoma study 6 (chromophobe type)
Tumor tissue samples from the kidney of patients with chromophobe renal cell carcinoma (cRCC).
Control normal kidney tissue
Normal fetal kidney tissue samples.

HCC study 18 (very advanced) / normal liver tissue

Relative Expression (log2-ratio):-2.8047247
Number of Samples:3 / 10
Experimental HCC study 18 (very advanced)
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control normal liver tissue
Normal liver tissue samples obtained from the healthy livers of patients undergoing resection for hepatic hemangioma, focal nodular hyperplasia, adenoma/cystadenoma, neuroendocrine tumor, and living donor liver transplantation.

HCC study 18 (early) / normal liver tissue

Relative Expression (log2-ratio):-2.7818823
Number of Samples:5 / 10
Experimental HCC study 18 (early)
Tumor tissue samples obtained from liver of patients with early hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Early HCC cases included well- to moderately differentiated tumors measuring 2-5 cm without vascular invasion/satellites, or 2-3 well-differentiated nodules measuring <3 cm (size range: 3-45 mm). Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control normal liver tissue
Normal liver tissue samples obtained from the healthy livers of patients undergoing resection for hepatic hemangioma, focal nodular hyperplasia, adenoma/cystadenoma, neuroendocrine tumor, and living donor liver transplantation.

HCC study 18 (very early) / normal liver tissue

Relative Expression (log2-ratio):-2.7461777
Number of Samples:5 / 10
Experimental HCC study 18 (very early)
Tumor tissue samples obtained from liver of patients with very early hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very early HCC cases included well-differentiated tumors measuring ≤2 cm in diameter with no vascular invasion/satellites (size range: 8-20 mm). Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control normal liver tissue
Normal liver tissue samples obtained from the healthy livers of patients undergoing resection for hepatic hemangioma, focal nodular hyperplasia, adenoma/cystadenoma, neuroendocrine tumor, and living donor liver transplantation.